IMPRESS Trial: Navigating the Switch to Chemo From a TKI

Dr Mark Kris discusses the details of the IMPRESS trial, which assessed the effect of discontinuing gefitinib in patients with EGFR-mutant lung cancer who have developed resistance to the drug.